Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Myeloproliferative neoplasm (MPN) transformed to acute myeloid leukemia (MPN-AML), MPN in accelerated phase (MPN-AP), and high-risk primary myelofibrosis (PMF) are associated with a poor response to therapy and very short survival. Several reports have suggested clinical activity of hypomethylating...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Res
Egile Nagusiak: Badar, Talha, Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Cortes, Jorge E., Pemmaraju, Naveen, Pierce, Sherry R., Newberry, Kate J., Daver, Naval, Verstovsek, Srdan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546869/
https://ncbi.nlm.nih.gov/pubmed/26183878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.06.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak